Results of Clinical Trials and Late Breaking Session

Abstract submissions are now closed.

Abstracts Submission Terms & Conditions

The Euretina ‘Results of Clinical Trials and Late Breaking Session’ will be a showcase for the latest innovative and breakthrough research topics available before the meeting begins on 19th September 2024.

Terms & Conditions

– The Results of Clinical Trials and Late Breaking Abstract submission portal opens Thursday 21st March, 2024 and will be closing Wednesday 19th June, 2024 (23:59 CEST).

– Please note that you must be an EURETINA Member in order to submit a Results of Clinical Trials and Late Breaking Abstract. If you are not a member please CLICK HERE to join. 

– Presenting authors must be ophthalmologists or researchers.

– Co-authors must be ophthalmologists, researchers or other healthcare professionals that have contributed to the project.

– Each applicant may submit a maximum of 2 Results of Clinical Trials and Late Breaking Abstracts.

If you choose to submit an abstract(s) we will use your personal details to keep you updated on its status including whether it has been accepted for presentation at the Euretina Congress. If your abstract(s) is accepted for presentation at the Euretina Congress your contact details (name and email address) will be sent to a third-party Audio-Visual Company in order for them to contact you in relation to uploading your presentation.

Review & Evaluation

– Abstracts focussing on the first presentation of results of a major clinical trial are encouraged for submission.

– All submitted abstracts will be reviewed before a final selection is made.

– Specific topics that need to be covered in the Congress programme will be considered before making the final selection of accepted abstracts. The decision of the Euretina Review Committee is final.

– If your abstract is accepted, you will be informed of this by email over the summer, 2024. 

– It is not possible to reschedule the assigned time of an accepted abstract.

Abstract Submission

All submitted abstracts must be in English and follow the structured format below:

– Title (250 characters max)

– Purpose (100 words max)

– Setting/Venue (50 words max)

– Methods (200 words max)

– Results (200 words max)

– Conclusions (200 words max)

All abstracts MUST be submitted in the presenting author’s name.

Financial Disclosure: Please indicate Yes/No. If applicable please clearly list your financial interest in the subject matter or if you receive funds from any mentioned companies.

Further Instructions

– Presentations titles must not include company names.

– Accepted presentations must not include company branded slides.

– Formulae should, in general, be avoided.

– When using abbreviations or acronyms for the first time, care should be taken to spell them out in full with the abbreviation in parentheses after the full word(s) the first time it appears in the text. The abbreviation should be used alone thereafter.

– There is an embargo on oral presentations until the first day of the annual Congress programme.

– Euretina does not take any ownership of the copyright of a presentation. However, presenters are required to sign a Transfer of Rights document at the time of the presentation upload.

– Accepted presentations will be displayed on EURETINA On Demand after the Congress.

For any queries, please contact [email protected].

Closing Date: Wednesday 19th June (23.59 CEST).